Cytosorbents Corporation (NASDAQ:CTSO) went up to recover about 10.74% since recording its record low price of $6.6. The stock experienced -2.66% slump, arriving at $7.31 on 01/11/2019. During the day, the stock price traveled from $7.17 to $7.5577. This company shares are 117.51% off its target price of $15.9 and the current market capitalization stands at $237.72M. The recent change has given its price a -20.69% deficit over SMA 50 and -51.1% deficit over its 52-week high. The stock witnessed -16.74% declines, -32.06% declines and -41.75% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CTSO’s volatility during a week at 7.18% and during a month it has been found around 7.24%.Cytosorbents Corporation (CTSO) Top Holders
Institutional investors currently hold around $60 million or 26.6% in CTSO stock. Look at its top three institutional owners. Blackrock Inc. owns $14.34 million in Cytosorbents Corporation, which represents roughly 6.03% of the company’s market cap and approximately 23.9% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 1,228,116 shares of the stock are valued at $8.98 million. The third largest holder is State Street Corp, which currently holds $3.44 million worth of this stock and that ownership represents nearly 1.45% of its market capitalization.
At the end of September reporting period, 40 institutional holders increased their position in Cytosorbents Corporation (NASDAQ:CTSO) by some 1,342,272 shares, 33 decreased positions by 966,860 and 14 held positions by 5,938,274. That puts total institutional holdings at 8,247,406 shares, according to SEC filings. The stock grabbed 12 new institutional investments totaling 457,905 shares while 10 institutional investors sold out their entire positions totaling 391,388 shares.Cytosorbents Corporation (NASDAQ:CTSO) Insider Trades
Multiple company employees have indulged in significant insider trading. Cytosorbents Corporation disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President and CEO Chan Phillip P. has sold 24,337 shares of Cytosorbents Corporation (CTSO) in trading session dated Dec. 07, 2018. These shares are worth $228,038 and were traded at $9.37 each. The SEC filing shows that Chan Phillip P. performed a sale of 11,418 shares. The President and CEO disposed these shares by way of transaction on Sep. 07, 2018. The company’s shares were given away at $14.65 per share worth to an income of some $167,274 on account of Chan Phillip P..
Director, Kraus Al, sold 26,000 common shares of Cytosorbents Corporation (CTSO) in the open market. In a transaction dated Aug. 30, 2018, the shares were put up for sale at an average price of $14.47, raking in a sum of $376,220. After this sale, 125,046 common shares of CTSO are directly owned by the insider, with total stake valued at $914,086.
In the transaction dated Aug. 29, 2018, the great number of shares disposed came courtesy the COO; Capponi Vincent disposed a total of 20,000 shares at an average price of $14, amounting to approximately $280,000. The insider now directly owns 332,768 shares worth $2,432,534.
Several analysts have released their opinion on Cytosorbents Corporation (NASDAQ:CTSO), with 0 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.